GMCN-508B (LentiRed)
2021-1101-001
Phase 1 gene_therapy active
Quick answer
GMCN-508B (LentiRed) for Transfusion Dependent Beta-Thalassemia is a Phase 1 program (gene_therapy) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Transfusion Dependent Beta-Thalassemia
- Phase
- Phase 1
- Modality
- gene_therapy
- Status
- active